NICE deals final blow for Roche's Avastin in breast cancer
This article was originally published in Scrip
Roche's Avastin (bevacizumab) has again fallen foul of NICE, the health technology appraisal body for England and Wales. The institute has today published final guidance rejecting the drug when used with Roche’s Xeloda (capecitabine) in first-line treatment of metastatic breast cancer.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.